Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…
https://etira.life/wp-content/uploads/2024/11/ER-reduced.png13861070Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-11-18 10:01:462026-01-02 11:10:37First patient dosed in ERX-315-101 Clinical Trial
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath, MD, PhD to…
https://etira.life/wp-content/uploads/2024/10/Board.png516656Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-10-08 07:14:252026-01-02 11:14:22Drs. Jenkins and Stebbing join Etira Board
Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
https://etira.life/wp-content/uploads/2024/09/Unknown.jpeg8191276Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-09-23 10:22:362026-01-02 11:23:40Validation of ERX-208 in Ovarian Cancer
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
https://etira.life/wp-content/uploads/2024/09/image.png15682324Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-09-04 10:06:482026-01-02 12:28:10ERX-315-001 SITE INITIATION VISIT @TKCC
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
https://etira.life/wp-content/uploads/2024/08/shutterstock_700277188_edited.jpeg690812Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-08-01 11:49:472026-01-02 12:26:55ERX-315 CLINICAL TRIAL APPROVED BY HREC
Melbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
https://etira.life/wp-content/uploads/2024/07/shutterstock_125779055-scaled.jpg25602127Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-07-10 12:16:072026-01-02 12:25:40Etira’s Australian partner MMIC expands
Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
https://etira.life/wp-content/uploads/2024/06/image.jpeg12641756Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-06-20 10:43:312026-01-02 12:24:43DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release.jpg5631000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-05-15 12:36:582026-01-02 12:23:51ERX-315 SUBMITTED FOR HREC APPROVAL
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
https://etira.life/wp-content/uploads/2024/05/Unknown-scaled.jpeg19202560Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-04-10 11:35:082026-01-02 12:21:28ERX-208 potency in Ovarian Cancer
Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
https://etira.life/wp-content/uploads/2024/01/image.png8661098Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-01-24 11:44:062026-01-02 12:19:56Targeting LIPA in ovarian cancer
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
First patient dosed in ERX-315-101 Clinical Trial
NewsDrs. Jenkins and Stebbing join Etira Board
NewsValidation of ERX-208 in Ovarian Cancer
NewsERX-315-001 SITE INITIATION VISIT @TKCC
NewsERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsEtira’s Australian partner MMIC expands
NewsDECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsERX-315 SUBMITTED FOR HREC APPROVAL
NewsERX-208 potency in Ovarian Cancer
NewsTargeting LIPA in ovarian cancer
News